Section of Young Adult Hip Surgery, Division of Sports Medicine, Department of Orthopaedic Surgery, Rush Medical College of Rush University, Rush University Medical Center, Chicago, Illinois, USA.
Department of Orthopaedic Surgery, Rush Medical College of Rush University, Rush University Medical Center, Chicago, Illinois, USA.
Am J Sports Med. 2022 Aug;50(10):2629-2636. doi: 10.1177/03635465221105469.
There is a paucity of information in the literature on midterm outcomes of endoscopic gluteus medius and/or minimus repair with concomitant labral treatment using only modern surgical techniques.
To define the minimal clinically important difference (MCID) and Patient Acceptable Symptom State (PASS) at a minimum of 5 years postoperatively for patients undergoing endoscopic hip abductor repair with routine capsular closure.
Case series; Level of evidence, 4.
Consecutive patients who underwent primary endoscopic repair of gluteus medius and/or minimus tears between January 2012 and December 2015 by the senior author were eligible for inclusion. Patient-reported outcome scores were assessed preoperatively and at 5 years postoperatively: Hip Outcome Score-Activities of Daily Living (HOS-ADL), HOS-Sport Specific (HOS-SS), modified Harris Hip Score (mHHS), 12-item International Hip Outcome Tool (iHOT-12), and visual analog scale (VAS) for pain. The MCID was uniquely calculated using the distribution method, and the PASS was determined via the anchor-based method utilizing receiver operating characteristic curves and Youden index.
A total of 46 patients were included in the study. The majority were female (87.0%), with a mean ± standard deviation age of 59.1 ± 8.9 years and body mass index of 27.3 ± 6.9. Significant postoperative improvements ( < .001) in each of the 5 patient-reported outcomes were observed at 5 years postoperatively. The MCID threshold values were calculated as follows: HOS-ADL, 11.5; HOS-SS, 15.1; mHHS, 13.3; iHOT-12, 11.8; and VAS, 15.8. The PASS thresholds were calculated as follows: HOS-ADL, 75.7; HOS-SS, 79.7; mHHS, 81.2; and iHOT-12, 60.8. A majority of patients achieved a clinically significant outcome, with 96.2% of patients reaching a threshold score for the MCID or PASS for at least 1 patient-reported outcome.
Endoscopic hip abductor repair with concomitant arthroscopic labral treatment has a high rate of achievement of clinically significant outcomes and survivorship at a minimum 5-year follow-up. We defined the MCID for the HOS-ADL, HOS-SS, mHHS, iHOT-12, and VAS outcome scores to be 11.5, 15.1, 13.3, 11.8, and 15.8, respectively. The PASS threshold scores for the HOS-ADL, HOS-SS, mHHS and iHOT-12 scores of 75.7, 79.7, 81.2, and 60.8, respectively. Future researchers and clinicians can use the MCID and PASS values established in this study to better evaluate mid-term outcomes of patients undergoing hip abductor repair.
目前文献中关于使用现代外科技术治疗伴或不伴盂唇病变的内镜臀中肌和/或小肌修复的中期结果的信息很少。
定义行内镜髋关节外展肌修复术并常规行囊闭合并治疗盂唇病变的患者在术后至少 5 年时的最小临床重要差异(MCID)和可接受症状状态(PASS)。
病例系列;证据水平,4 级。
符合纳入标准的是 2012 年 1 月至 2015 年 12 月期间由资深作者行原发性内镜修复臀中肌和/或小肌撕裂的连续患者。在术前和术后 5 年评估患者报告的结果评分:髋关节结果评分-日常活动(HOS-ADL)、髋关节特异性评分(HOS-SS)、改良 Harris 髋关节评分(mHHS)、12 项国际髋关节结果工具(iHOT-12)和疼痛视觉模拟评分(VAS)。MCID 是通过分布法独特计算的,PASS 是通过利用接收者操作特征曲线和 Youden 指数的基于锚的方法确定的。
共纳入 46 例患者。大多数为女性(87.0%),平均年龄为 59.1±8.9 岁,平均体重指数为 27.3±6.9。术后 5 年时,5 项患者报告结果均有显著改善(<0.001)。MCID 阈值计算如下:HOS-ADL,11.5;HOS-SS,15.1;mHHS,13.3;iHOT-12,11.8;VAS,15.8。PASS 阈值计算如下:HOS-ADL,75.7;HOS-SS,79.7;mHHS,81.2;iHOT-12,60.8。大多数患者达到了有临床意义的结果,96.2%的患者在至少 1 项患者报告结果中达到了 MCID 或 PASS 的阈值评分。
行内镜髋关节外展肌修复术并同期行关节镜下盂唇治疗,在至少 5 年的随访中,有很高的达到临床显著结果和生存率的概率。我们定义了 HOS-ADL、HOS-SS、mHHS、iHOT-12 和 VAS 评分的 MCID 分别为 11.5、15.1、13.3、11.8 和 15.8。HOS-ADL、HOS-SS、mHHS 和 iHOT-12 的 PASS 阈值分别为 75.7、79.7、81.2 和 60.8。未来的研究人员和临床医生可以使用本研究中建立的 MCID 和 PASS 值来更好地评估髋关节外展肌修复患者的中期结果。